PHILADELPHIA – The immune system struggles to defeat cancer or chronic infections because many of the T cells that leap into action end up “exhausted,” rendering them ineffective against disease. That path to exhaustion and what triggers it is a crucial one that researchers aim to better understand so they can stop or divert more T cells from heading down this path. Now, a new Penn Medicine study published in the journal Immunity, paints a clearer picture of the molecular mechanisms of newly formed, or “precursor,” T cells driving the transformation. It’s a discovery that could inform current treatments and the development of more powerful immunotherapies, cancer drugs, or both.
This early developmental decision was dependent on a key transcription factor (TF) known as TCF-1. TF is a protein that helps transcribe DNA into RNA. Genetically sequencing T cells early during chronic viral infection uncovered how TCF-1 plays a role in programing a T cell to either barrel toward exhaustion or become an “effector” T cell that holds its ground in the fight. This observation has implication for both chronic infections and cancer.
“What we've done here is effectively go back in time for exhausted T cells,” said senior author E. John Wherry, PhD, chair of the department of Systems Pharmacology and Translational Therapeutics and director of the Penn Institute of Immunology. “If you understand what the exhausted T cell precursors look like and how they're working in terms of their internal wiring, we can rewire and do better than nature intended with immunotherapies. So, essentially what you're doing is trying to prevent the developmental path of exhaustion or change its trajectory, rather than take the end product of that pathway, the exhaustion, and try to re-engineer it.”
The study builds off a previous one in Nature in June 2019 from Wherry's lab that found that a protein known as TOX, which varies in amount in different immune cells types, controls the identity of the cells that become exhausted. But the findings didn’t tell researchers exactly when or how different that path of development was from the effector T cells and memory T cells—two important types of T cells to battle infections.
Effector T cells kill offending cancer cells and germs like bacteria or viruses. If an infection or tumor is cleared, most of this pool dies, but a subset persists. This set undergoes more rewiring and forms long-lived, self-renewing memory T cells capable of mounting a rapid recall response should an invader be detected a second time.
“The new paper identifies the early steps demonstrating the precursors to the developmental path toward exhaustion, and that they are different from the precursors that can give rise to effector and memory T cells,” Wherry said. “We identified the molecular mechanisms, so we now know what wiring the precursor population needs to form into exhausted T cells and what protects that population from being depleted.”
The findings could help inform immunotherapies and potentially identify patients that might benefit most from some treatments, the preclinical study suggests. If the T cell pathways could be mapped out early, then patients more likely to respond well to treatments such as checkpoint inhibitors could potentially be identified. Immune checkpoint inhibitors block proteins that stop the immune system from attacking cancer cells.
Unexpectedly, the researchers also discovered more about the dual role of a checkpoint pathway, known as PD-1. Checkpoint molecules like PD-1 are good targets for drugs, but they also appear to have a functional role early on in exhausted T cells, because they prevent them from being over stimulated. “Precursors of exhausted T cells might actually benefit from expressing PD-1 early on, while later on we want to block this pathway to reinvigorate these exhausted T cells,” Wherry said.
The next step is to better understand whether this latest study can be applied to intentionally engineer the T cells to perform a certain way.
“These findings help define early exhaustion events and have implications to help distinguish exhausted T cells from effector and memory T cell developmental programs in settings such as cancer and chronic infections,” the authors wrote.
Co-authors include Zeyu Chen, Zhicheng Ji, Shin Foong Ngiow, Sasikanth Manne, Zhangying Cai, Alexander C. Huang, John Johnson, Ryan P. Staupe, Bertram Bengsch, Caiyue Xu, Sixiang Yu, Makoto Kurachi1, Ramin S. Herati, Laura A. Vella, Amy E. Baxter, Jennifer E. Wu, Omar Khan, Jean-Christophe Beltra ,Josephine R. Giles, Erietta Stelekati, Laura M. McLane, Chi Wai Lau, Xiaolu Yang, Shelley L. Berger, Golnaz Vahedi, and Hongkai Ji.
This work was supported by grants from the National Institutes of Health (AI105343,
AI117950, AI082630, AI112521, AI115712, AI108545, CA210944, HG009518, CA234842, AI114852, CA009140), Stand Up 2 Cancer, and the Parker Institute for Cancer Immunotherapy.
Editor’s note: Wherry has a patent licensing agreement on the PD-1 pathway and is a founder of Arsenal Biosciences.
Penn Medicine is one of the world’s leading academic medical centers, dedicated to the related missions of medical education, biomedical research, and excellence in patient care. Penn Medicine consists of the Raymond and Ruth Perelman School of Medicine at the University of Pennsylvania (founded in 1765 as the nation’s first medical school) and the University of Pennsylvania Health System, which together form a $7.8 billion enterprise.
The Perelman School of Medicine has been ranked among the top medical schools in the United States for more than 20 years, according to U.S. News & World Report's survey of research-oriented medical schools. The School is consistently among the nation's top recipients of funding from the National Institutes of Health, with $425 million awarded in the 2018 fiscal year.
The University of Pennsylvania Health System’s patient care facilities include: the Hospital of the University of Pennsylvania and Penn Presbyterian Medical Center—which are recognized as one of the nation’s top “Honor Roll” hospitals by U.S. News & World Report—Chester County Hospital; Lancaster General Health; Penn Medicine Princeton Health; and Pennsylvania Hospital, the nation’s first hospital, founded in 1751. Additional facilities and enterprises include Good Shepherd Penn Partners, Penn Home Care and Hospice Services, Lancaster Behavioral Health Hospital, and Princeton House Behavioral Health, among others.
Penn Medicine is powered by a talented and dedicated workforce of more than 40,000 people. The organization also has alliances with top community health systems across both Southeastern Pennsylvania and Southern New Jersey, creating more options for patients no matter where they live.
Penn Medicine is committed to improving lives and health through a variety of community-based programs and activities. In fiscal year 2018, Penn Medicine provided more than $525 million to benefit our community.